Biogen, AbbVie once-monthly MS injection wins U.S. FDA approval
May 27 (Reuters) - The U.S. Food and Drug Administration on Friday approved a once-monthly injection for multiple sclerosis from Biogen Inc and AbbVie Inc.
The self-administered, under-the-skin injection, Zinbryta, is designed to treat adults with relapsing forms of the disease. (http://1.usa.gov/1TILwDg) (Reporting by Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila)